Table 1.
Echocardiographic measurements showing improved LV function in 12/15-LOX−/− and PUFA-fed mice
| Control Day 0 |
MI Day 1 |
MI Day 5 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameters | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA | WT | WT + PUFA | 12/15-LOX−/− | 12/15-LOX−/− + PUFA |
| n | 5 | 4 | 5 | 4 | 6 | 5 | 6 | 4 | 6 | 5 | 9 | 7 |
| Heart rate, beats/min | 445 ± 16 | 465 ± 7 | 427 ± 11 | 418 ± 16 | 499 ± 16 | 475 ± 16 | 451 ± 18 | 462 ± 16 | 445 ± 17 | 484 ± 26 | 427 ± 8 | 436 ± 4 |
| End-diastolic volume, µl | 53.3 ± 5 | 56.8 ± 5 | 45.0 ± 2 | 53.3 ± 4 | 96.6 ± 17* | 79.2 ± 6*† | 62.8 ± 4*† | 61.3 ± 4*† | 125.9 ± 17* | 102.2 ± 11* | 95.2 ± 5*† | 106.3 ± 20*† |
| End-systolic volume, µl | 20.1 ± 3 | 24.8 ± 3 | 19.2 ± 2 | 22.0 ± 4 | 85.1 ± 16* | 68.0 ± 6*† | 52.0 ± 3*† | 52.3 ± 4*† | 113.2 ± 15* | 83.4 ± 138*† | 82.6 ± 4*† | 93.2 ± 19*† |
| Posterior wall thickness at systole, mm | 1.1 ± 0.02 | 1.05 ± 0.06 | 1.05 ± 0.02 | 1.05 ± 0.04 | 0.54 ± 0.05* | 0.46 ± 0.02*† | 0.54 ± 0.03* | 0.47 ± 0.03*† | 0.50 ± 0.05* | 0.50 ± 0.02* | 0.51 ± 0.03* | 0.50 ± 0.05* |
| Ejection fraction | 63 ± 4 | 62 ± 2 | 67 ± 2 | 64 ± 6 | 13 ± 1* | 14 ± 2* | 17 ± 1*† | 15 ± 1 | 10 ± 1* | 20 ± 5*† | 13 ± 0.7*† | 14 ± 3*† |
Values are expressed as means ± SE; n indicates sample size. No infarct served as the day 0 naïve control group. LV, left ventricular; LOX, lipoxygenase; PUFA, polyunsaturated fatty acid; MI, myocardial infarction.
*
P < 0.05 vs. day 0 wild-type (WT) control;
†
P < 0.05 vs. WT mice at the respective day time point.